

# POLYPEPTIDE GROUP AG CHF0.01

ISIN: CH1110760852 WKN: 111076085 Asset Class: Stock

|                   |                       |
|-------------------|-----------------------|
| <b>Company</b>    | 2024/10/18 17:30:09   |
| <b>Price</b>      | <b>29.75</b>          |
|                   | CHF                   |
| <b>Difference</b> | <b>-0.67% (-0.20)</b> |



|                        |                                                                          |
|------------------------|--------------------------------------------------------------------------|
| <b>Contact Details</b> |                                                                          |
| POLYPEPTIDE GROUP AG   | Tel: +41-43-502-05-80                                                    |
| --                     | Fax: +                                                                   |
| Neuhofstrasse 24       | Web: <a href="http://www.polypeptide.com">http://www.polypeptide.com</a> |
| 6340 Baar              | E-mail: <a href="mailto:info@polypeptide.com">info@polypeptide.com</a>   |

## Company Profile

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023        |                        | 2022        |                        | 2021        |                        |
|---------------------------------------|-------------|------------------------|-------------|------------------------|-------------|------------------------|
|                                       | Assets      | Liabilities and equity | Assets      | Liabilities and equity | Assets      | Liabilities and equity |
| <b>Current assets</b>                 | 303,651,000 |                        | 248,405,000 |                        | 343,596,000 |                        |
| <b>Common stock capital</b>           |             | 280,000                |             | 298,000                |             | 312,000                |
| <b>Fixed assets</b>                   | 337,013,000 |                        | 320,133,000 |                        | 272,957,000 |                        |
| <b>Equity capital of a company</b>    |             | 354,435,000            |             | 416,372,000            |             | 436,402,000            |
| <b>Cash and cash equivalents</b>      | 88,980,000  |                        | 37,055,000  |                        | 141,231,000 |                        |
| <b>Accrued liabilities</b>            |             | 24,879,000             |             | 28,746,000             |             | 45,123,000             |
| <b>Other assets</b>                   | -           |                        | -           |                        | -           |                        |
| <b>Current liabilities</b>            |             | 164,050,000            |             | 94,843,000             |             | 107,720,000            |
| <b>Prepayments and accrued income</b> | -           |                        | -           |                        | -           |                        |
| <b>Non-current liabilities</b>        |             | 122,178,000            |             | 57,322,000             |             | 72,431,000             |
| <b>Different income</b>               |             | -                      |             | -                      |             | -                      |
| <b>Other liabilities</b>              |             | 30,730,000             |             | 9,291,000              |             | 10,674,000             |
| <b>Total assets</b>                   | 640,664,000 | 640,664,000            | 568,538,000 | 568,538,000            | 616,554,000 | 616,554,000            |

## Balance notes

|                            | 2023   | 2022   | 2021   |
|----------------------------|--------|--------|--------|
| <b>Accounting standard</b> | IFRS   | IFRS   | IFRS   |
| <b>Employees</b>           | 1,273  | 1,219  | 1,101  |
| <b>Equity ratio</b>        | 55.32% | 73.24% | 70.78% |
| <b>Debt-equity ratio</b>   | 80.76% | 36.55% | 41.28% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 11.68% | -2.64% | 21.04% |

# POLYPEPTIDE GROUP AG CHF0.01

ISIN: CH1110760852 WKN: 111076085 Asset Class: Stock

## Income statement

|                                                                      | 2023        | 2022        | 2021        |
|----------------------------------------------------------------------|-------------|-------------|-------------|
| <b>Turnover</b>                                                      | 311,256,000 | 282,031,000 | 304,878,000 |
| <b>Net income</b>                                                    | -49,976,000 | 7,796,000   | 51,069,000  |
| <b>EBIT</b>                                                          | -52,636,042 | 11,727,620  | 72,379,089  |
| <b>Operating income before taxes</b>                                 | -56,585,000 | 7,595,000   | 64,674,000  |
| <b>Cash Flow</b>                                                     | 35,446,000  | 5,480,000   | 61,977,000  |
| <b>Net interest income</b>                                           | -7,120,000  | -3,425,000  | -3,344,000  |
| <b>Research and development expenses</b>                             | 1,423,000   | 1,247,000   | 1,520,000   |
| <b>Income taxes</b>                                                  | -6,609,000  | -200,000    | 13,605,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | 0           | 0           | 0           |
| <b>Revenues per employee</b>                                         | 260,179     | 246,193     | 294,660     |

## Board of Directors

|                   |                                      |
|-------------------|--------------------------------------|
| Beat In-Albon     | Member of the administrative board   |
| Jane Salik        | Member of the administrative board   |
| Patrick Aebischer | Member of the administrative board   |
| Philippe Weber    | Member of the administrative board   |
| Erik Schropp      | Member of the administrative board   |
| Peter Wilden      | Chairman of the administrative board |

## Members of Management Board

|                       |                               |
|-----------------------|-------------------------------|
| Juan-José Gonzalez    | Chairman of Managing Board    |
| Christina del Vecchio | Member of Executive Committee |
| Jens Fricke           | Member of Executive Committee |
| Marc Augustin         | Member of Executive Committee |
| Neil Thompson         | Member of Executive Committee |
| Stéphane Varray       | Member of Executive Committee |